STERIS plc (NYSE:STE) Shares Acquired by Carnegie Investment Counsel

Carnegie Investment Counsel lifted its position in STERIS plc (NYSE:STE) by 3.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 56,355 shares of the medical equipment provider’s stock after acquiring an additional 1,647 shares during the quarter. Carnegie Investment Counsel’s holdings in STERIS were worth $13,668,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. West Coast Financial LLC raised its position in shares of STERIS by 2.8% during the 3rd quarter. West Coast Financial LLC now owns 1,640 shares of the medical equipment provider’s stock valued at $398,000 after buying an additional 45 shares during the period. Taylor Frigon Capital Management LLC lifted its stake in shares of STERIS by 0.8% in the 2nd quarter. Taylor Frigon Capital Management LLC now owns 6,175 shares of the medical equipment provider’s stock valued at $1,356,000 after purchasing an additional 46 shares during the last quarter. First Hawaiian Bank grew its holdings in shares of STERIS by 0.4% during the 1st quarter. First Hawaiian Bank now owns 13,857 shares of the medical equipment provider’s stock worth $3,115,000 after purchasing an additional 50 shares during the period. J.Safra Asset Management Corp increased its position in shares of STERIS by 77.9% during the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 53 shares during the last quarter. Finally, Mather Group LLC. raised its holdings in STERIS by 7.6% in the 2nd quarter. Mather Group LLC. now owns 763 shares of the medical equipment provider’s stock valued at $172,000 after buying an additional 54 shares during the period. 94.69% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Christopher S. Holland sold 473 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $239.68, for a total value of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares of the company’s stock, valued at approximately $139,493.76. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher S. Holland sold 473 shares of the business’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the sale, the director now directly owns 582 shares in the company, valued at approximately $139,493.76. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.

STERIS Stock Up 0.3 %

Shares of STERIS stock opened at $226.90 on Friday. STERIS plc has a 52-week low of $195.47 and a 52-week high of $248.24. The company has a 50 day moving average of $236.75 and a 200 day moving average of $225.84. The company has a quick ratio of 1.49, a current ratio of 2.33 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $22.38 billion, a P/E ratio of 56.30 and a beta of 0.84.

STERIS (NYSE:STE) last issued its earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.16. The business had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.27 billion. STERIS had a net margin of 7.36% and a return on equity of 13.85%. The company’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.00 EPS. As a group, research analysts forecast that STERIS plc will post 9.06 EPS for the current fiscal year.

STERIS Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 20th. Investors of record on Thursday, September 5th were given a $0.57 dividend. This is an increase from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date was Thursday, September 5th. This represents a $2.28 annualized dividend and a yield of 1.00%. STERIS’s dividend payout ratio is 56.58%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. KeyCorp lifted their price target on shares of STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. Stephens restated an “overweight” rating and set a $260.00 price target on shares of STERIS in a research note on Wednesday, August 7th. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research note on Wednesday, August 7th. StockNews.com raised STERIS from a “hold” rating to a “buy” rating in a research note on Tuesday, August 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $246.00.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.